Replies to post #99895 on Biotech Values

[DewDiligence]

Can you imagine that FDA's demand for a complicated molecule such as Copaxone would be less (without bioequivalence) than for a simple compound such as aspirin?

The FDA sometimes grants a waiver of the bioequivalence requirement for generic drugs that are injected.